Ascorbic Acid: A New Player of Epigenetic Regulation in LPS-gingivalis Treated Human Periodontal Ligament Stem Cells

Guya D. Marconi,1 Luigia Fonticoli,2 Simone Guarnieri,3 Marcos F. X. B. Cavalcanti,4 Sara Franchi,5 Valentina Gatta,5 Oriana Trubiani,2, Jacopo Pizzicannella,6 and Francesca Diomede2

1Department of Medical, Oral and Biotechnological Sciences, University "G. d’Annunzio" of Chieti-Pescara, 66100 Chieti, Italy
2Department of Innovative Technologies in Medicine & Dentistry, University "G. d’Annunzio" of Chieti-Pescara, 66100 Chieti, Italy
3Department of Neuroscience, Imaging and clinical Sciences-Center for Advanced Studies and Technology (CAST), University "G. d’Annunzio” of Chieti-Pescara, 66100 Chieti, Italy
4Nove de Julho University, 01506-000 São Paulo, Brazil
5Department of Psychological, Health and Territorial Sciences, School of Medicine and Health Sciences, "G. d’Annunzio" University, 66100 Chieti, Italy
6“Ss. Annunziata” Hospital, ASL 02 Lanciano-Vasto-Chieti, 66100 Chieti, Italy

Correspondence should be addressed to Oriana Trubiani; trubiani@unich.it

Received 27 October 2020; Revised 21 December 2020; Accepted 31 December 2020; Published 19 January 2021

Academic Editor: Ayman Mahmoud

Copyright © 2021 Guya D. Marconi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

In the last few years, regenerative medicine based its success on the role of human mesenchymal stem cells (hMSCs). Human MSCs are characterized from two properties: self-renewal ability and multipotent differentiation potential [1]. Furthermore, hMSCs can differentiate and expand into mature cells as osteoblast, adipocytes, and chondroblasts and maintain the stem cell population [2]. They express specific surface markers, such as CD105, CD90, and CD73 and lack the expression for HLA-DR, CD45, CD34, and other hematopoietic markers [3]. These multipotent cells are located in different sites of the body. The bone marrow represents the gold standard tissue to isolate the hMSCs, but they can be also detected in the adipose and dental tissues, peripheral blood, umbilical cord blood, and amniotic...
membrane [4]. Several studies have been focused on alternative tissue sources for adult mesenchymal stem cells, like the dental pulp, dental follicle, apical papilla, periodontal ligament, and palatine tonsil [5]. In particular, hMSCs, derived from oral tissues, as dental pulp and periodontal ligament, are able to regulate tooth homeostasis and help tissue repair [6]. In particular, stem cells derived from human periodontal ligament (hPDLSCs) showed the ability to differentiate into mesenchymal lineages. One of the most important features of hPDLSCs is the capacity to protect against infectious diseases related to their immunomodulatory properties [7, 8]. Periodontal disease is an infectious disease that leads to the progressive destruction of the periodontal ligament tissue and to the bone and tooth loss. Traditional clinical approaches for periodontal diseases are still insufficient to induce the full tissue regeneration of periodontium [9]. The hPDLSCs are not tumorigenic, maintain their classic phenotype and karyotype features in long-term passage cultures and are characterized by immunoregulatory properties [10, 11]. All hMSCs play an active role in the immune response; they interact with natural killer cells, dendritic cells, B lymphocytes, and T lymphocytes. Therefore, hMSCs avoid improper activation of T lymphocytes and limit the immune response during healing [12–14]. Nowadays, a great number of researches are investigating on the MSC response to inflammatory events in combination with antioxidant substances. Gram-negative bacteria showed on the outer of the cell membrane a component called lipopolysaccharide (LPS), and it is considered to be a major link for virulence in periodontitis [15]. Periodontitis is usually sustained from several micro-organisms placed in the oral cavity, like Porphyromonas gingivalis (P. gingivalis, G), that afflicts a large number of people [16, 17]. Ascorbic acid (AA), known as vitamin C or ascorbate, consumed as a dietary supplement is a water-soluble vitamin that helps many enzyme activities [18]. AA is deeply involved in the reduction of reactive oxygen species (ROS) and showed a key role as an antiseptics agent [19]. When added to the cell culture, AA increased cell proliferation, upregulated the cell pluripotency marker expression [20], promoted MSCs regeneration of the periodontal ligament tissue, and protect inflammatory conditions induced by 2-hydroxyethyl methacrylate (HEMA) treatment reducing the intracellular inflammatory pathway [21].

Studies have shown that there exist a correlation between the periodontal diseases and some biomarkers, like micro-RNAs (miRNAs). miRNAs, noncoding small molecule RNAs, have influenced the development of periodontitis, as miR-146a, miR-128, and miR-200b [22–24], miR-210 is located in the protection of the periodontitis; other than this, it has been identified in the triggering of several pathologies like cancers and immunological diseases [25]. Recent studies reported that miR-210 can be considered a key factor in the critical promotion of the osteogenic and angiogenic processes other than in cell survival [26, 27].

The purpose of the present study was to analyze the response of hPDLSCs to LPS-G, as a periodontitis in vitro model, alone or in presence of AA, in order to establish the potential protective role of AA on the inflammatory process triggered by LPS-G and in the preservation of the hPDLSCs reservoir.

2. Materials and Methods

2.1. Ethic Statement. Ethical Committee at the Medical School, “G. d’Annunzio” University, Chieti, Italy (number 266/April 17, 2014) approved the present study protocol. Informed consent form was filled and signed by all patients enrolled in the present research. All the procedures are in compliance with the 1964 Helsinki declaration and its later revisions, other than following the ethical standards of the institutional and/or national research committee.

2.2. Cell Culture Establishment. To collect hPDLSCs, we have enrolled six patients in good general health and without oral cavity diseases. They were to undergo surgical procedures to start the orthodontic treatment. After the collection, the periodontal ligament fragments were washed five times with phosphate-buffered saline solution (PBS, Lonza, Basel, Switzerland) [28]. The washed tissue fragments were placed in a culture dish in an incubator at 37°C in a humidified atmosphere of 5% CO2 in air. The mesenchymal stem cell growth medium—chemically defined (MSCGM-CD, Lonza) was used as a medium and changed every two days. Isolated cells were migrated spontaneously from the tissue fragments after two weeks of culture [29, 30].

2.3. Human PDLSC Characterization by FACS Analysis. Human PDLSCs were washed in PBS and then analyzed for CD14, CD34, CD45, CD73, CD90, and CD105 expressions [31]. Briefly, cells were stained for CD45, CD73, and CD90 with fluorescein isothiocyanate-conjugated antibodies and for CD14, CD34, and CD105 with phycoerythrin-conjugated antibodies. After staining procedures, FACStar-plus flow-cytometry system running CellQuest software (Becton-Dickinson, Mountain View, CA, USA) was used. All reagents used for flow cytometry were purchased from Becton Dickinson [32].

2.4. In Vitro hPDLSC Multilineage Differentiation. The capacity of hPDLSCs to differentiate into mesengenic lineages, as adipogenic and osteogenic differentiation, was evaluated by means of colorimetric detection and reverse transcription polymerase chain reaction (RT-PCR). In particular, hPDLSCs were placed in a 24 multiwell with a density of 2×104 cells/well. To induce adipogenic differentiation, cells were maintained in MSCBM-CD supplemented with 10 nmol/L dexamethasone, 10 nmol/L 3-isobutyl-1-methylxanthine, 5 mg/mL insulin, and 60 mmol/L indomethacin for 28 days. The medium was refreshed every 3 days. Oil Red O solution (Sigma-Aldrich, Milan, Italy) was used to evaluate the adipogenic phenotype, staining the lipid droplet at cytoplasmic level. To induce the osteogenic commitment, the hPDLSCs were placed in a 24-multiwell with a density of 2×104 cells/well. Cells were cultured with MSCBM-CD supplemented with 10 nmol/L dexamethasone, 10 nmol/L betaglycerophosphate (Sigma–Aldrich), and 50 mmol/L ascorbic acid for 21 days. Alizarin red S (Sigma–Aldrich) solution was used to stain the calcium depositions. Differentiated
hPDLSCs were visualized to the inverted light microscopy Leica DMIL (Leica Microsystem, Milan, Italy). Furthermore, to evaluate the specific gene expression for adipogenic and osteogenic differentiation, RT-PCR has been performed. FABP4 and PPARγ were evaluated for adipogenesis commitment, and RUNX-2 and ALP were analyzed for osteogenesis [33].

2.5. Study Design. All experiments were performed in triplicate with hPDLSCs at passage 2. The study design is reported as follows:

(i) Untreated hPDLSCs, used as negative control (CTRL)

(ii) hPDLSCs treated for 24 h with 50 μg mL⁻¹ with ascorbic acid (AA)

(iii) hPDLSCs treated for 24 h with ultrapure lipopolysaccharide from P. gingivalis (tlrl-ppgp1ps, InvivoGen, San Diego, CA, USA) 5 μg mL⁻¹ (LPS-G)

(iv) hPDLSCs co-treated for 24 h with 50 μg mL⁻¹ with ascorbic acid (AA) and LPS-G 5 μg mL⁻¹ (LPS-G+AA)

2.6. MTT Assay. Cell viability of all experimental groups was determined using MTT colorimetric assay. Human PDLSCs
were cultured in a 96-well at a density of 2 × 10^3 cells/well. To evaluate the cell metabolic activity at 24, 48, and 72 h of culture, 20 μL of MTT solution (CellTiter 96 AQueous One Solution reagent, Promega, Milan, Italy) was added to each well. Samples were maintained in the incubator, and after 3 h, the plates were read at 490 nm wavelength by means of a microplate reader (Synergy HT, BioTek Instruments, Winooski, VT, USA) [34].

2.7. Immunofluorescence and Confocal Laser Scanning Microscope (CLSM) Analyses. Sample fixation was performed with a solution of 4% of paraformaldehyde in 0.1 M of PBS (Lonza) [35, 36]. The following steps were performed: cells were permeabilized with 0.5% Triton X-100 in PBS for 10 min; samples blocking with 5% skimmed milk in PBS for 30 min [37]; primary antibodies (anti-NFκB, 1:200, Santa Cruz Biotechnology; anti-MyD800, Thermo Fisher Scientific; anti-DNMT1, 1:200, EpiGentek; and anti-p300, 1:200, OriGene) incubation for 2 h at room temperature; and finally, secondary antibody (Alexa Fluor 568 red fluorescence-conjugated goat anti-rabbit antibody, 1:200, Molecular Probes, Invitrogen, Eugene, OR, USA) incubation for 1 h at 37°C. Cells were stained for 1 h with Alexa Fluor 488 phalloidin green fluorescent conjugate (1:400, Molecular Probes) and for 1 h with TOPRO (1:200, Molecular Probes) to mark the cytoskeleton actin and nuclei, respectively [38, 39]. The Zeiss LSM800 confocal system (Zeiss, Jena, Germany) has been used to acquire microphotographs.

2.8. Western Blot Analysis. Proteins (50 μg) from all sample groups were processed as previously described [40]. Sheets were incubated 12 h at 4°C in with primary antibodies to NFκB (1:500, Santa Cruz Biotechnology), MyD88 (1:1000, Thermo-Fisher Scientific), p300 (1:750, EpiGentek), DNMT1 (1:750, OriGene), and β-actin (1:1000, Santa Cruz Biotechnology) [41, 42]. Then, sheets were maintained at room temperature for 30 min with peroxidase-conjugated secondary antibody diluted 1:1000 in 1x TBS, 5% milk, and 0.05% Tween-20 [43]. The ECL method was used for band visualization, and the protein level were measured by means of the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA) [44].

2.9. ROS Analysis. Human PDLSCs were seeded in 35 mm imaging dish (μ-Dish, ibidi GmbH, Gräfelfing, D). Cells were treated for 24 h in culture medium containing 5 μg mL⁻¹ LPS-G; (hPDLSCs+LPS-G) or 5 μg mL⁻¹ LPS-G plus 50 μg/mL ascorbic acid (hPDLSCs+LPS-G+AA) or 50 μg/mL ascorbic acid (AA) or culture medium alone (control, hPDLSCs). At the selected time, the cells were washed with normal external solution (NES) containing (in mM): 125 NaCl, 5 KCl, 1 MgSO4, 1 KH2PO4, 5.5 glucose, 1 CaCl₂, 20 HEPES, and pH 7.4 and incubated with 10 μM of 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA, Thermo Fisher Scientific) at 37°C in a humidified incubator (for 30 min) maintaining for all procedures the respective culture media treatments. At the end of dye incubation, the cells were washed with NES and observed in NES alone (hPDLSCs) or maintaining in NES plus hPDLSCs+LPS-G or AA alone. For each condition, confocal images were randomly acquired using a Zeiss LSM800 microscope (Carl Zeiss), equipped with an inverted microscopy Axio-observer.D1 and an objective W-Plan-Apo 40X/1.3 DIC. Excitation was fixed at 488 nm and emission was collected, setting the filter set over 505–530 nm. The acquisition settings were maintained constant between specimens. Fiji distribution of ImageJ software was used to analyze the captured images.

2.10. MicroRNA Quantization. MicroRNAs were extracted using the PureLink RNA mini kit (Life Technologies), treated with the RNase-Free DNase Set (Qiagen, Venlo, Netherlands) according to the manufacturer’s instructions and quantified by means Nanodrop2000 (Thermo Scientific, Waltham, MA, USA). Gene sequences were from NCBI (http://www.ncbi.nlm.nih.gov), and RNA sequences for miR-210 were used into the Universal ProbeLibrary (UPL) Assay Design Center software (https://www.rocheappliedscience.com) to identify primers and UPL probe. Total RNA (50–200 ng) was retro-transcribed with High-Capacity cDNA Reverse-Transcription Kit (Life Technologies, Milan, Italy). MicroRNA quantization was performed using stem-loop RT primers designed with a modification to include the UPL #21 sequence-binding site [45]. The target amount, normalized to endogenous reference 18S/RNU44 and relative to a calibrator, was given by 2^ΔΔCt and/or 2^ΔΔCt methods (Life Technologies).

2.11. Statistical Analysis. Statistical evaluation has been performed using GraphPad 4.0 software using t-test and ordinary one-way ANOVA followed by post hoc Bonferroni’s multiple comparisons tests. Values of P < 0.05 were considered statistically significant.

3. Results

3.1. Characterization of hPDLSCs Culture. Human hPDLSCs show a typical fibroblastoid morphology, and they are able to adhere to plastic surfaces (Figure 1(a)). The minimal
criteria defined by the International Society for Cellular Therapy were used to characterize hPDLSCs. Human PDLSCs are able to differentiate into adipogenic and osteogenic phenotypes as demonstrated in Figure 1. Alizarin Red solution demonstrated with a red staining the calcium deposition (Figure 1(b)), and Oil Red O solution stained the intracellular lipid vacuoles (Figure 1(c)). Graph bars of RT-PCR validated the qualitative data, showing an upregulation of FABP4, PPARγ, RUNX-2, and ALP in differentiated cells (Figures 1(e) and 1(f)). Flow cytometry results showed the positive expression for CD73, CD90, and CD105 and the negative expression for CD14, CD34, and CD45 (Figure 1(d)).

3.2. MTT Cell Viability Assay. To evaluate the effects of AA, LPS-G, and AA in coadministration with LPS-G on hPDLSCs viable cells, the MTT assay was executed. During experiment, the hPDLSCs treated with AA showed a similar rate to the CTRL group, while hPDLSCs treated with LPS-G (5 μg/mL) evidenced a significant reduction of viable cells.
with respect to the other samples. After 24 h, the presence of AA reverts the effects of LPS-G showing a similar cell viability rate to the samples. A similar trend was reported after 48 and 72 hours of treatment with AA, LPS-G, and LPS-G+AA. The AA treatment showed beneficial effects, in terms of proliferation rate, after 24, 48, and 72 hours of treatment on both cell cultures (Figure 2).

3.3. Signaling Pathway NFκB, MyD88, p300, and DNMT1 Analyses. Microphotographs captured by means of CLSM showed the intracellular expression of NFκB, MyD88, p300, and DNMT1 (Figures 3–6). The hPDLSCs treated with LPS-G showed cell morphological changes compared to the untreated cells. The cells cotreated with LPS-G and AA evidenced a protective effect, hence the hPDLSCs a morphology reasonably comparable to the untreated hPDLSCs (CTRL). Furthermore, to confirm signaling network stimulated by LPS-G administration in hPDLSCs, the expression of NFκB, MyD88, p300, and DNMT1 was examined after 24 h of culture. Immunofluorescence experiments to detect NFκB,
MyD88, p300, and DNMT1 localization were executed in hPDLSCs tested in all conditions stated above. Images in Figures 3–5 showed an increased fluorescence signal derived from NFκB, MyD88, and p300 immunostaining in hPDLSCs treated with LPS-G compared to the hPDLSCs under other experimental conditions, in particular to the cells treated with AA. Immunofluorescence detection for DNMT1 showed a decrease in LPS-G-treated cells, meanwhile the expression level increases in cells cotreated with LPS-G and AA, similar to the CTRL and AA samples (Figure 6). LPS-G operates on the receptor and initiates a molecular cascade upregulating MyD88 and causing NFκB to translocate at the nuclear level (Figures 4 and 5).

3.4. NFκB, MyD88, p300, and DNMT1 Protein Expressions. Western blotting assay was evaluated to assess NFκB, MyD88, p300, and DNMT1 protein expressions. In Figure 7, bands of NFκB, MyD88, and p300 were augmented in LPS-G administered in hPDLSCs, while in cells treated with LPS-G+AA, a downregulation of NFκB, MyD88, and

---

**Figure 5:** Immunofluorescence analyses of the expression of p300. (a) Untreated hPDLSCs (CTRL). (b) Cells treated with AA (AA). (c) Cells treated with LPS-G (LPS-G). (d) Cells co-treated with LPS-G and AA (LPS-G+AA). p300 was stained in red fluorescence (Alexa Fluor 568 for secondary antibody). Cytoskeleton actin was stained in green fluorescence (Alexa-phalloidin 488). Cell nuclei were stained in blue fluorescence (TO-PRO). Merged image showed the overlap of all abovementioned channels. Scale bar: 10μm.
p300 was existent. DNMT1 protein is expressed in hPDLSCs and in cells treated with AA and cotreated with LPS-G+AA.

3.5. ROS Production. To verify the ROS production stimulated by LPS-G, hPDLSCs were loaded with the cell-permeant H2DCFDA a probe, used as an indicator for ROS. Figures were taken in live cells by means of confocal microscopy, and the single cell fluorescence recorded was finally offline investigated. In Figure 8(a), typical images acquired in our experimental circumstances are shown. Comparing the images taken, in the LPS-G-treated cells, there is an evident increase in emitted fluorescence with respect to the others, while the cotreatment of LPS-G in presence of AA appeared quite similar to that obtained in hPDLSC or AA alone. Quantitative results (Figure 8(b)) showed a growth in ROS production in 5 μg mL⁻¹ LPS-G-treated hPDLSCs vs. hPDLSCs (means ± S.E.M.: LPS-G 0.1 ± 0.02 vs. hPDLSCs 0.04 ± 0.005). The co-presence of

---

**Figure 6:** Immunofluorescence analyses of the expression of DNMT1. (a) Untreated hPDLSCs (CTRL). (b) Cells treated with AA (AA). (c) Cells treated with LPS-G (LPS-G). (d) Cells co-treated with LPS-G and AA (LPS-G+AA). DNMT1 was stained in red fluorescence (Alexa Fluor 568 for secondary antibody). Cytoskeleton actin was stained in green fluorescence (Alexa-phalloidin 488). Cell nuclei were stained in blue fluorescence (TO-PRO). Merged image showed the overlap of all abovementioned channels. Scale bar: 10 μm.
ascorbic acid successfully appeared to be able to block the ROS production induced by LPS-G (LPS-G+AA: 0.05 ± 0.001), while the AA alone did not modify the ROS basal levels acquired in hPDLSC samples (AA: 0.040 ± 0.003).

3.6. miR-210 Expression. miR-210 expression was downregulated in hPDLSCs administered with LPS-G, while in cells treated with AA and cotreated with LPS-G+AA, the miRNA-210 level is comparable to the CTRL group (Figure 9).
Porphyromonas gingivalis localized in the gum plaque, as is sustained by a definition relationship between oral and systemic health [3]. LPS-G to mimic in vitro the periodontitis model.

Transcription [48].

Epigenetic modifications are a complex molecular mechanism with chemical modifications of DNA and their related proteins that lead to the activation or inactivation of some gene transcription [48].

In the present study, hPDLSCs were administered with LPS-G to mimic in vitro the periodontitis model.

**4. Discussion**

Periodontitis is a chronic inflammatory illness, worldwide distributed and often correlated to many other chronic diseases such as cardiovascular disease, inflammatory bowel disease, rheumatoid arthritis, respiratory tract infection, and Alzheimer’s disease, exhibiting a given attention in the relationship between oral and systemic health [3–5]. Periodontitis is sustained by a definite oral microorganism that is localized in the gum plaque, as Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, and Aggregatibacter actinomycetemcomitans. The periodontal disease worsening brings to the loss of periodontal ligament, alveolar bone, and consequently the tooth leakage [9].

The maintenance of the periodontal health becomes a real challenge to ameliorate the quality life of a wide part of population [10]. The human oral microbiome can be considered essential in the pathogenesis and in the development of the periodontal disease.

Periodontal tissue damage is a result of an aberrant host response to the bacterial infection and immune response activated from the polymorphonuclear leukocytes (PMNs) that are critically implicated versus the periodontal pathogens. This antimicrobial response at the infection site triggers numerous intracellular signaling pathways, including reactive oxygen species release (ROS), that can be considered the principal cause for the periodontal tissue injury in periodontal illness [46, 47].

The inflammation, involved in the stimulation and maintenance of the periodontitis, induced the epigenetic modifications in the periodontal ligament niche. Epigenetic modifications are a complex molecular mechanism with chemical modifications of DNA and their related proteins that lead to the activation or inactivation of some gene transcription [48].

In the present study, hPDLSCs were administered with LPS-G to mimic in vitro the periodontitis model.

The in vivo periodontitis scenario is very complex and involves the interaction of several cell bacteria and factors. The use of ultrapure preparation of LPS-G in a human cellular model could understand the mechanisms of the inflammatory response in periodontitis and the development of future clinical treatments. As previously reported, to study the periodontitis model, it is important to consider two key factors: (i) the LPS-G preparation, “standard” or “ultrapure” [49] and (ii) the in vitro model, mouse or human, to better reflect the in vivo situation. The use of mouse models could underestimate the role of LPS-G in the triggering and sustaining of human pathology [50].

LPS-G treatment activated the MyD88 and p300 signal transduction and induced NFκB nuclear translocation. Meanwhile, the immunofluorescence and protein analyses showed a suppression in the expression of DNMT1 [51, 52]. As previously reported, DNMT1 expression is downregulated in oral epithelial cell and hPDLSCs treated with P. gingivalis (whole bacteria) or LPS-G [53].

AA supplemented with the diet exerts an antioxidant outcome, downregulating the free radical production and operating as a cofactor in cell functions [54, 55]. AA is also considered vital in the maintenance of periodontal health for its role in the downregulation of ROS production [56]. As earlier described, the role of AA in periodontal disease is in the avoiding and reducing the progression of the destruction process, stimulating the differentiation of periodontal ligament progenitor cells [57]. In the present study, the effects of AA in the periodontal disease in vitro model has been assessed in terms of cell viability, inflammatory pathways, gene expression, ROS production, and miRNA 210 expression. The treatment with AA increased the viability of hPDLSCs, while the LPS-G treatment showed a decrease in cell viability; moreover, the co-treatment of AA and LPS-G restore the conditions obtained in CTRL samples.

LPS-G treatment induces the inflammatory intracellular signaling cascades, as NFκB, MyD88, and p300 pathways. NFκB is a family of transcription factors implicated in the activation of inflammatory genes and in periodontal disease progression. NFκB showed a redox-sensitive potential for ROS in different tissues, as endothelial and vascular smooth muscle; other than that, it has been extensively studied as a proinflammatory nuclear transcription factor in a rat model related to the hypertension [58]. As reported in the literature, in an experimental rat model, the treatment with AA lead to a downexpression of NFκB and a reduction of the excessive ROS production, responsible of blood vessel inflammation, as beneficial effects [59, 60], p300 is a general transcriptional factor that can change the chromatin structure from heterochromatin to euchromatin, in order to enhance the binding of transcriptional factors to promoters [61]. p300 is necessary for the transcriptional activity of NFκB, a crucial mediator of inflammatory responses [62, 63].

In our periodontitis in vitro model, LPS-G augmented the expression of NFκB, MyD88, and p300. Moreover, our results reported a decrease expression of DNMT1 in LPS-G-treated samples. Meanwhile, the co-treatment of LPS-G and AA showed a downregulation of NFκB, MyD88, and
p300 and conversely an upregulation of DNMT1 in a similar way to the untreated cells.

Latest study has demonstrated that the NFκB pathway can be initiated to promote proinflammatory cytokine expression in periodontitis [64]; in particular, NFκB can be activated in hPDLSCs treated with LPS-G [65]. NFκB signaling pathway is inhibited by miR-210, as reported by Zhang et al., leading to a reduction of the inflammatory cascade in osteoarthritis [66]. Our results suggest that the cells treated with LPS-G showed an activation of NFκB signaling and a reduction in the expression of miR210, as also reported by Jia et al. [67]. miR-210 is decreased in patients with periodontitis in comparison to the healthy individuals. When cells were co-treated with LPS-G and AA, it showed an overexpression of miR210 that could inhibit the NFκB pathway induced by AA treatment. LPS administration stimulated both p38 MAPK and NFκB signaling pathways [67], while miR-210 overexpression repressed the p38MAPK/NFκB pathway in LPS-stimulated PDLCs; similar results was obtained by Chen and Li [68].

5. Conclusions

In conclusion, the present work reported that miR-210 level was downregulated and the inflammatory signaling pathways are activated in an in vitro periodontitis model, while the co-treatment with AA could attenuate the inflammatory response. However, the results in our study should be further investigated by future in vivo models.

Data Availability

The data used to support the findings of the present study are available from the corresponding authors upon request.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

GDM, LF, and SG contributed to data collection and analysis, data interpretation, preparation of figures, drafting of manuscript, editing and revising manuscript, and approving final version of manuscript. MFXBC, SF, and VG contributed to data analysis, data interpretation, preparation of figures, revising manuscript, and approving final version of manuscript. OT, JP, and FD conceived the study and contributed to study design, experiments, data analysis, data interpretation, preparation of figures, editing and revising manuscript, and approving final version of manuscript. Guya D. Marconi and Luigia Ponticoli contribute equally to the work. Jacopo Pizzicannella and Francesca Diomede contribute equally to the work as senior author.

Acknowledgments

This research was funded by the University “G. d’Annunzio” Chieti-Pescara (AT2019_Trubiani/14327).

References

[1] Q. Z. Zhang, A. L. Nguyen, W. H. Yu, and A. D. Le, “Human oral mucosa and Gingiva,” Journal of dental research, vol. 91, no. 11, pp. 1011–1018, 2012.

[2] A. R. Sanz, F. S. Carrion, and A. P. Chaparro, “Mesenchymal stem cells from the oral cavity and their potential value in tissue engineering,” Periodontology 2000, vol. 67, no. 1, pp. 251–267, 2015.

[3] M. Tatullo, B. Codispoti, A. Pacifi ci et al., “Potential use of human periapical cyst mesenchymal stem cells (hPCy-MSCs) as a novel stem cell source for regenerative medicine applications,” Frontiers in cell and developmental biology, vol. 5, 2017.

[4] M. Tatullo, M. Marrelli, and F. Paduano, “The regenerative medicine in oral and maxillofacial surgery: the most important innovations in the clinical application of mesenchymal stem cells,” International journal of medical sciences, vol. 12, no. 1, pp. 72–77, 2015.

[5] Y. Chen, X. Wang, J. Fang et al., “Mesenchymal stem cells participate in oral mucosa carcinogenesis by regulating T cell proliferation,” Clinical immunology, vol. 198, pp. 46–53, 2019.

[6] P. T. Sharpe, “Dental mesenchymal stem cells,” Development, vol. 143, no. 13, pp. 2273–2280, 2016.

[7] O. Andrukhov, C. Behm, A. Blufstein, and X. Rausch-Fan, “Immunomodulatory properties of dental tissue-derived mesenchymal stem cells: Implication in disease and tissue regeneration,” World journal of stem cells, vol. 11, no. 9, pp. 604–617, 2019.

[8] L. L. Zhou, W. Liu, Y. M. Wu, W. L. Sun, C. E. Dorfer, and K. M. Fawzy El-Sayed, “Oral mesenchymal stem/progenitor cells: the immunomodulatory masters,” Stem cells international, vol. 2020, Article ID 1327405, 2020.

[9] B. L. Pihlstrom, B. S. Michalowicz, and N. W. Johnson, “Periodontal diseases,” Lancet, vol. 366, no. 9499, pp. 1809–1820, 2005.

[10] H. Yang, L. N. Gao, Y. An et al., “Comparison of mesenchymal stem cells derived from gingival tissue and periodontal ligament in different incubation conditions,” Biomaterials, vol. 34, no. 29, pp. 7033–7047, 2013.

[11] O. Trubiani, J. Pizzicannella, S. Caputi et al., “Periodontal ligament stem cells: current knowledge and future perspectives,” Stem cells and development, vol. 28, no. 15, pp. 995–1003, 2019.

[12] M. E. Castro-Manrreza and J. J. Montesinos, “Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications,” Journal of immunology research, vol. 2015, Article ID 394917, 20 pages, 2015.

[13] O. Trubiani, G. D. Marconi, S. D. Pierdomenico, A. Piattelli, F. Diomede, and J. Pizzicannella, “Human oral stem cells, biomaterials and extracellular vesicles: a promising tool in bone tissue repair,” International Journal of Molecular Sciences, vol. 20, no. 20, p. 4987, 2019.

[14] T. S. Rajan, S. Giacoppo, O. Trubiani et al., “Conditioned medium of periodontal ligament mesenchymal stem cells exert anti-inflammatory effects in lipopolysaccharide-activated mouse motoneurons,” Experimental cell research, vol. 349, no. 1, pp. 152–161, 2016.

[15] C. Li, B. Li, Z. Dong et al., “Lipopolysaccharide differentially affects the osteogenic differentiation of periodontal ligament stem cells and bone marrow mesenchymal stem cells through Toll-like receptor 4 mediated nuclear factor κB pathway,” Stem cell research & therapy, vol. 5, no. 3, p. 67, 2014.
[16] G. Hajishengallis, "Periodontitis: from microbial immune subversion to systemic inflammation," Nature reviews Immunology, vol. 15, no. 1, pp. 30–44, 2015.

[17] P. N. Papapanou and C. Susin, "Periodontitis epidemiology: is periodontitis under-recognized, over-diagnosed, or both?," Periodontology 2000, vol. 75, no. 1, pp. 45–51, 2017.

[18] F. Diomede, G. D. Marconi, S. Guarnieri et al., "A novel role of ascorbic acid in anti-inflammatory pathway and ROS generation in HEMA treated dental pulp stem cells," Materials, vol. 13, no. 1, p. 130, 2020.

[19] B. Frei, L. England, and B. N. Ames, "Ascorbate is an outstanding antioxidant in human blood plasma," Proceedings of the National Academy of Sciences, vol. 86, no. 16, pp. 6377–6381, 1989.

[20] P. D. Potdar and S. B. D’Souza, "Ascorbic acid induces in vitro proliferation of human subcutaneous adipose tissue derived mesenchymal stem cells with upregulation of embryonic stem cell pluripotency markers Oct 4 and SOX 2," Human cell, vol. 23, no. 4, pp. 152–155, 2010.

[21] F. L. Wei, C. Y. Qu, T. L. Song et al., "Vitamin C treatment promotes mesenchymal stem cell sheet formation and tissue regeneration by elevating telomerase activity," Journal of Cellular Physiology, vol. 227, no. 9, pp. 3216–3224, 2012.

[22] S. Y. Jiang, D. Xue, Y. F. Xie et al., "The negative feedback regulation of microRNA-146a in human periodontal ligament cells after Porphyromonas gingivalis lipopolysaccharide stimulation," Inflammation Research, vol. 64, no. 6, pp. 441–451, 2015.

[23] H. S. Na, M. H. Park, Y. R. Song et al., "Elevated microRNA-128 in periodontitis mitigates tumor necrosis Factor-α response via p38 signaling pathway in macrophages," Journal of Periodontology, vol. 87, no. 9, pp. E173–E182, 2016.

[24] A. Z. Kalea, R. Hoteit, J. Suvan et al., "Upregulation of gingival tissue miR-200b in obese periodontitis subjects," Journal of Dental Research, vol. 94, 3_supplement, pp. 59s–69s, 2015.

[25] K. Dang and K. A. Myers, "The role of hypoxia-induced miR-210 in cancer progression," International Journal of Molecular Sciences, vol. 16, no. 12, pp. 6353–6372, 2015.

[26] J. Pizzicannella, F. Diomede, A. Gugliandolo et al., "3D printing PLA/gingival stem cells’ EVs upregulate miR-2861 and -210 during osteoangiogenesis commitment," International Journal of Molecular Sciences, vol. 20, no. 13, p. 3256, 2019.

[27] J. Pizzicannella, M. Cavalcanti, O. Trubiani, and F. Diomede, "MicroRNA 210 mediates VEGF upregulation in human periodontal ligament stem cells cultured on 3D hydroxyapatite ceramic scaffold," International Journal of Molecular Sciences, vol. 19, no. 12, p. 3916, 2018.

[28] A. Gugliandolo, F. Diomede, P. Cardelli et al., "Transcriptomic analysis of gingival mesenchymal stem cells cultured on 3D bioprinted scaffold: a promising strategy for neuroregeneration," Journal of biomedical materials research Part A, vol. 106, no. 1, pp. 126–137, 2018.

[29] F. Diomede, N. Zini, J. Pizzicannella et al., "5-Aza exposure improves reprogramming process through embryoid body formation in human gingival stem cells," Frontiers in genetics, vol. 9, 2018.

[30] O. Trubiani, E. Toniato, D. Di Iorio et al., "Morphological analysis and interleukin release in human gingival fibroblasts seeded on different denture base acrylic resins," International journal of immunopathology and pharmacology, vol. 25, no. 3, pp. 637–643, 2012.

[31] M. Dominici, K. Le Blanc, I. Mueller et al., "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement," Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006.

[32] P. Ballerini, F. Diomede, N. Petragnani et al., "Conditioned medium from relapsing-remitting multiple sclerosis patients reduces the expression and release of inflammatory cytokines induced by LPS- gingivalis in THP-1 and MO3.13 cell lines," Cytokine, vol. 96, pp. 261–272, 2017.

[33] B. Sinjari, J. Pizzicannella, M. D’Aurora et al., "Curcumin/liposome nanotechnology as delivery platform for anti-inflammatory activities via NFκB/ERK/pERK pathway in human dental pulp treated with 2-hydroxyethyl methacrylate (HEMA)," Frontiers in physiology, vol. 10, 2019.

[34] M. F. X. B. Cavalcanti, D. A. Maria, N. de Isla et al., "Evaluation of the proliferative effects induced by low-level laser therapy in bone marrow stem cell culture," Photomedicine and laser surgery, vol. 33, no. 12, pp. 610–616, 2015.

[35] F. Diomede, M. D’Aurora, A. Gugliandolo et al., "A novel role in skeletal segment regeneration of extracellular vesicles released from periodontal-ligament stem cells," International journal of nanomedicine, vol. 13, pp. 3805–3825, 2018.

[36] A. Mazzatenta, G. D. Marconi, V. Macchi et al., "Coexpression of galanin and nestin in the chemoreceptor cells of the human carotid body," Respiratory, vol. 885, pp. 77–82, 2015.

[37] J. Pizzicannella, R. Rabozzi, O. Trubiani, and G. Di Giampaolo, "HTK solution helps to preserve endothelial integrity of saphenous vein: an immunohistochemical and ultrastructural analysis," Journal of biological regulators and homeostatic agents, vol. 25, no. 1, pp. 93–99, 2011.

[38] C. Di Giulio, G. D. Marconi, S. Zara et al., "Selective expression of galanin in neuronal-like cells of the human carotid body," Advances in experimental medicine and biology, vol. 860, pp. 315–323, 2015.

[39] O. Trubiani, S. Guarnieri, F. Diomede et al., "Nuclear translocation of PKCa isoenzyme is involved in neurogenic commitment of human neural crest-derived periodontal ligament stem cells," Cellular signalling, vol. 28, no. 11, pp. 1631–1641, 2016.

[40] S. Giacopppo, S. R. Thangavelu, F. Diomede et al., "Anti-inflammatory effects of hypoxia-preconditioned human periodontal ligament cell secretome in an experimental model of multiple sclerosis: a key role of IL-37," The FASEB Journal, vol. 31, no. 12, pp. 5592–5608, 2017.

[41] S. Mammana, A. Gugliandolo, E. Cavalli et al., "Human gingival mesenchymal stem cells pretreated with vesicular moringin nanostructures as a new therapeutic approach in a mouse model of spinal cord injury," The FASEB Journal, vol. 33, no. 3, pp. 6370–6382, 2019.

[42] F. Diomede, M. D’Aurora, A. Gugliandolo et al., "Biofunctionalized scaffold in bone tissue repair," International Journal of Molecular Sciences, vol. 19, no. 4, p. 1022, 2018.

[43] F. Diomede, N. Zini, V. Gatta et al., "Human periodontal ligament stem cells cultured onto cortico-cancellous scaffold drive bone regenerative process," European cells & materials, vol. 32, pp. 181–201, 2016.

[44] A. Mazzatenta, G. D. Marconi, S. Zara, A. Cataldi, A. Porzionario, and C. Di Giulio, "In the carotid body, galanin
is a signal for neurogenesis in young, and for neurodegeneration in the old and in drug-addicted subjects,” *Frontiers in Physiology*, vol. 5, 2014.

[45] F. Diomede, I. Merciario, S. Martinotti et al., “miR-2861 is involved in osteogenic commitment of human periodontal ligament stem cells grown onto 3D scaffold,” *J Biol Regul Homeost Agents*, vol. 30, no. 4, pp. 1009–1018, 2016.

[46] D. R. Miller, I. B. Lamster, and A. I. Chasens, “Role of the polymorphonuclear leukocyte in periodontal health and disease,” *Journal of clinical periodontology*, vol. 11, no. 1, pp. 1–15, 1984.

[47] T. E. Van Dyke and G. A. Hoop, “Neutrophil function and oral disease,” *Critical Reviews in Oral Biology & Medicine*, vol. 1, pp. 117–133, 2016.

[48] F. Diomede, S. R. Thangavelu, I. Merciario et al., “Porphyromonas gingivalis lipopolysaccharide stimulation in human periodontal ligament stem cells: role of epigenetic modifications to the inflammation,” *European Journal of Histochemistry*, vol. 61, 2017.

[49] C. Behm, A. Blufstein, S. Y. Abhari et al., “Response of human mesenchymal stromal cells from periodontal tissue to LPS depends on the purity but not on the LPS source,” *Mediators of Inflammation*, vol. 2020, Article ID 8704896, 17 pages, 2020.

[50] B. Nativel, D. Couret, P. Giraud et al., “Porphyromonas gingivalis lipopolysaccharides act exclusively through TLR4 with a resilience between mouse and human,” *Scientific Reports*, vol. 7, no. 1, 2017.

[51] F. Diomede, M. Zingariello, M. Cavalcanti et al., “MyD88/ERK/NFkB pathways and pro-inflammatory cytokines release in periodontal ligament stem cells stimulated by Porphyromonas gingivalis,” *European Journal of Histochemistry*, vol. 61, no. 2, 2017.

[52] J. Pizzicannella, F. Diomede, I. Merciario et al., “Endothelial committed oral stem cells as modelling in the relationship between periodontal and cardiovascular disease,” *Journal of Cellular Physiology*, vol. 233, no. 10, pp. 6734–6747, 2018.

[53] L. Yin and W. O. Chung, “Epigenetic regulation of human β-defensin 2 and CC chemokine ligand 20 expression in gingival epithelial cells in response to oral bacteria,” *Mucosal immunology*, vol. 4, no. 4, pp. 409–419, 2011.

[54] A. C. Carr and B. Frei, “Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans,” *The American journal of clinical nutrition*, vol. 69, no. 6, pp. 1086–1107, 1999.

[55] S. J. Padayatty, A. Katz, Y. Wang et al., “Vitamin C as an antioxidant: evaluation of its role in disease prevention,” *Journal of the American College of Nutrition*, vol. 22, no. 1, pp. 18–35, 2003.

[56] I. L. Chapple and J. B. Matthews, “The role of reactive oxygen and antioxidant species in periodontal tissue destruction,” *Periodontology 2000*, vol. 43, no. 1, pp. 160–232, 2007.

[57] Y. Yan, W. Zeng, S. Song et al., “Vitamin C induces periodontal ligament progenitor cell differentiation via activation of ERK pathway mediated by PELP1,” *Protein & cell*, vol. 4, no. 8, pp. 620–627, 2013.

[58] F. C. Luft, “Angiotensin, inflammation, hypertension, and cardiovascular disease,” *Current hypertension reports*, vol. 3, no. 1, pp. 61–67, 2001.

[59] V. R. Baichwal and P. A. Baeuerle, “Apoptosis: Activate NF-xB or die?,” *Current Biology*, vol. 7, no. 2, pp. R94–R96, 1997.

[60] T. O. Ajibade, A. A. Oyaghemi, T. O. Omobowale, E. R. Asenuga, and K. O. Adigun, “Quercetin and vitamin C mitigate cobalt chloride-induced hypertension through reduction in oxidative stress and nuclear factor kappa beta (NF-kB) expression in experimental rat model,” *Biological Trace Element Research*, vol. 175, no. 2, pp. 347–359, 2017.

[61] D. J. Steger and J. L. Workman, “Remodeling chromatin structures for transcription: what happens to the histones?,” *BioEssays*, vol. 18, no. 11, pp. 875–884, 1996.

[62] W. Vanden Berghe, K. De Bosscher, E. Boone, S. Plaisance, and G. Haegeman, “The nuclear Factor-xB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter,” *The Journal of biological chemistry*, vol. 274, no. 45, pp. 32091–32098, 1999.

[63] J. Zhao, A. Y. Gong, R. Zhou, J. Liu, A. N. Eischeid, and X. M. Chen, “Downregulation of PCAF by miR-181a/b provides feedback regulation to TNF-α-Induced transcription of proinflammatory genes in liver epithelial cells,” *The Journal of Immunology*, vol. 188, no. 3, pp. 1266–1274, 2012.

[64] L. Golz, S. Memmert, B. Rath-Deschner et al., “Hypoxia and P. gingivalis Synergistically Induce HIF-1 and NF-xB Activation in PDL Cells and Periodontal Diseases,” *Mediators of Inflammation*, vol. 2015, Article ID 438085, 12 pages, 2015.

[65] W. X. Huang, Y. L. Zhan, Y. F. Zheng, Y. Han, W. J. Hu, and J. X. Hou, “Up-regulated ferritin in periodontitis promotes inflammatory cytokine expression in human periodontal ligament cells through transferrin receptor via ERK/P38 MAPK pathways,” *Clinical Science*, vol. 133, no. 1, pp. 135–148, 2019.

[66] D. W. Zhang, X. R. Cao, J. Li, and G. Y. Zhao, “MiR-210 inhibits NF-kappa B signaling pathway by targeting DR6 in osteoarthritids,” *Scientific Reports*, vol. 5, 2015.

[67] S. H. Jin, J. G. Zhou, X. Y. Guan, J. H. Bai, J. G. Liu, and L. W. Chen, “Development of an miRNA-Array-Based Diagnostic Signature for Periodontitis,” *Frontiers in Genetics*, vol. 11, 2020.

[68] Y. Chen and H. Li, “Alkannin protects human renal proximal tubular epithelial cells from LPS-induced inflammatory injury by regulation of microRNA-210,” *Biomedicine & Pharmacotherapy*, vol. 108, pp. 1679–1685, 2018.